erlotinib hydrochloride has been researched along with Pleural Effusion in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y; Gu, X; Liu, X; Zhao, L; Zhou, X | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Remo, A | 1 |
| Arai, S; Fukuda, K; Mukae, H; Nakagawa, T; Nanjo, S; Takeuchi, S; Taniguchi, H; Yamada, T; Yamaguchi, H; Yano, S | 1 |
| Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Chowbay, B; Goh, JW; Lee, P; Mancer, K; Tan, PH; Toh, CK | 1 |
1 trial(s) available for erlotinib hydrochloride and Pleural Effusion
| Article | Year |
|---|---|
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
6 other study(ies) available for erlotinib hydrochloride and Pleural Effusion
| Article | Year |
|---|---|
Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome | 2020 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed | 2015 |
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Topics: Amphiregulin; Anaplastic Lymphoma Kinase; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Microtubule-Associated Proteins; Mutation; Pleural Effusion; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Serine Endopeptidases; Xenograft Model Antitumor Assays | 2017 |
An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2007 |